Search results for "Vascularization"

showing 10 items of 519 documents

Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab.

2010

PURPOSE The purpose of this study was to report the visual outcome of intravitreal therapy with ranibizumab of choroidal neovascularization secondary to angioid streaks after 1-year follow-up. METHODS Nine patients (age, 58 +/- 4 years; range, 53-65 years) were treated with off-label intravitreal injections of 0.3 mg ranibizumab. Primary outcomes were best-corrected visual acuity changes (Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution and letters) and optical coherence tomography macular thickness changes. RESULTS Mean follow-up was 14 months (+/-2; range, 12-18 months). Mean visual acuity was 0.52 logarithm of the minimum angle of resolution and 30 …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuitymonoclonalAngiogenesis InhibitorsAntibodies Monoclonal HumanizedLoading doseChoroidal neovascularization; male; treatment outcome; injections; middle aged; vascular endothelial growth factor a; female; vitreous body; humans; retreatment; visual acuity; angiogenesis inhibitors; aged; angioid streaks; antibodies monoclonalInjectionsNeovascularizationOptical coherence tomographyOphthalmologyRanibizumabMedicineantibodiesHumansANTI-VEGFAgedintravitreal ranibizumabmedicine.diagnostic_testbusiness.industrySettore MED/30 - Malattie Apparato VisivoAntibodies MonoclonalGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseeye diseasesChoroidal NeovascularizationVitreous BodyOphthalmologyAngioid streaksChoroidal neovascularizationTreatment OutcomeRetreatmentAngioid StreaksFemalemedicine.symptomRanibizumabbusinessAngioid streak-related choroidal neovascularizationmedicine.drugRetina (Philadelphia, Pa.)
researchProduct

Prognostic implications of dipyridamole cardiac MR imaging: a prospective multicenter registry

2011

Purpose: To evaluate dipyridamole cardiac magnetic resonance (MR) imaging in the prediction of major events (MEs) in patients with ischemic chest pain in a large multicenter registry. Materials and Methods: Institutional ethics committee approval and written informed consent were obtained. A total of 1722 patients who were undergoing cardiac MR imaging for chest pain were included. Wall motion abnormalities (WMAs) at rest, hyperemia perfusion defect (PD), late gadolinium enhancement (LGE), and inducible WMA were analyzed (abnormal if more than one abnormal segment was seen) with the 17-segment model. A cardiac MR categorization was created: category 1, no PD, LGE, or inducible WMA; category…

MaleVasodilator AgentsMyocardial InfarctionMyocardial IschemiaCardiovascular magnetic-resonanceContrast Medialaw.inventionCoronary artery diseaseCoronary-artery-diseaseRandomized controlled triallawMyocardial RevascularizationProspective StudiesRegistriesMyocardial infarctionDipyridamoleMiddle AgedPrognosisManagementDipyridamoleCardiologyFemaleRadiologyArtifactsmedicine.drugChest Painmedicine.medical_specialtyMagnetic Resonance Imaging CineIschemic cascadeStatistics NonparametricAssociationTECNOLOGIA ELECTRONICAPredictive Value of TestsInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingWall motionAgedProportional Hazards ModelsChi-Square DistributionStress perfusionbusiness.industryReproducibility of ResultsIschemic cascademedicine.diseaseMr imagingMyocardial-infarctionDysfunctionCase-Control StudiesReperfusionIschemic chest painbusiness
researchProduct

Is Ranibizumab effective in stopping the loss of vision for Choroidal Neovascularization in Pathologic Myopia? A Long Term Follow-up Study

2010

Aim To assess the efficacy and safety of ranibizumab in the treatment of choroidal neovascularisation (CNV) caused by pathologic myopia (PM). Design Prospective, multicentre, interventional case series. Methods 40 eyes of 39 consecutive patients with PM and CNV were treated with ‘on demand’ intravitreal injection of ranibizumab 0.5 mg. Final best corrected visual acuity (BCVA) and its change from baseline were the main outcome measures. Changes in optical coherence tomography (OCT) central retinal thickness (CRT) were a secondary outcome. Results Mean age was 53±13 years and mean refractive error –13.5±6.5 D. Median follow-up was 13.3±2 (range 12–18) months. Fifteen eyes (37.5%) had previou…

MaleVisual Acuity/drug effectsRefractive errorgenetic structuresEye diseaseVisual AcuityVision disorderProspective StudiesFluorescein AngiographyMedicine(all)Neovascularisationmedicine.diagnostic_testAntibodies MonoclonalDrugsDiabetic retinopathyMiddle AgedFluorescein angiographySensory SystemsChoroidal neovascularizationmedicine.anatomical_structureMyopia DegenerativeIntravitreal InjectionsFemaleMyopia Degenerative/complicationsmedicine.symptomTomography Optical Coherencemedicine.drugAdultmedicine.medical_specialtyAntibodies Monoclonal HumanizedAntibodies Monoclonal/administration & dosageCellular and Molecular NeuroscienceRanibizumabOphthalmologymedicineHumansAgedbusiness.industryChoroidChoroidal Neovascularization/drug therapyOff-Label Usemedicine.diseaseChoroidal Neovascularizationeye diseasesOphthalmologyChoroidsense organsRanibizumabaged 80 and overbusinessFollow-Up Studies
researchProduct

Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density.

2001

Thrombospondin-1 (TSP-1) is a multifunctional platelet and extracellular matrix protein that is involved in angiogenesis. Under certain pathological conditions, e.g., malignant tumors, high concentrations of TSP-1 work as an angiogenic agonist. Here we examined 98 pancreatic carcinomas with respect to TSP-1 immunoreactivity and its correlation to intratumoral microvessel density (MVD), a representation of the overall degree of angiogenesis in carcinomas. Northern blot analysis for TSP-1 mRNA was performed in seven additional cases. Eighty-seven tumors showed strong TSP-1 immunoreactivity, nine carcinomas were only weakly positive, and two lesions were negative for TSP-1. TSP-1 immunoreactiv…

Maleendocrine systemPathologymedicine.medical_specialtyPancreatic diseaseAngiogenesisGene ExpressionBiologyAdenocarcinomaPathology and Forensic MedicineNeovascularizationThrombospondin 1immune system diseasesThrombospondin 1medicineBiomarkers TumorHumansRNA MessengerMolecular BiologyAgedAged 80 and overNeovascularization PathologicMicrocirculationvirus diseasesCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseBlotting NorthernImmunohistochemistryBlotPancreatic Neoplasmsmedicine.anatomical_structureTumor progressionAdenocarcinomaFemalemedicine.symptomPancreasVirchows Archiv : an international journal of pathology
researchProduct

Relationship between low lymphocyte count and major cardiac events in patients with acute chest pain, a non-diagnostic electrocardiogram and normal t…

2008

Risk stratification of patients with acute chest pain, non-diagnostic electrocardiogram and normal troponin (ACPneg) remains a challenge, partly because no standardized set of biomarkers with prognostic ability has been identified in this population. Lymphopenia has been associated with atherosclerosis progression and adverse outcomes in cardiovascular diseases; although its prognostic value in ACPneg is unknown. We sought to determine the relationship between the lymphocyte count obtained in the Emergency Department (ED) and the risk of the long-term all-cause mortality or myocardial infarction (MI) in patients with ACPneg.We analyzed 1030 consecutive patients admitted with ACPneg in our i…

Malemedicine.medical_specialtyAcute coronary syndromeChest Painmedicine.medical_treatmentPopulationMyocardial InfarctionRevascularizationDiagnosis DifferentialElectrocardiographyInternal medicinemedicineHumansMyocardial infarctionLymphocyte CounteducationSurvival analysisAgededucation.field_of_studybiologybusiness.industryVascular diseaseMiddle Agedmedicine.diseaseTroponinTroponinSurgerybiology.proteinFemaleMyocardial infarction diagnosisCardiology and Cardiovascular MedicinebusinessEmergency Service HospitalBiomarkersAtherosclerosis
researchProduct

Effect of invasive treatment on prognosis in non-ST-segment elevation acute coronary syndrome with or without systolic dysfunction.

2010

Introduction and objectives. Few data are available on the use of invasive treatment in patients with non-STsegment elevation acute coronary syndrome (NSTEACS) and systolic dysfunction. The aim of this study was to determine the effect of invasive treatment on the prognosis of patients with NSTEACS, with or without systolic dysfunction. Methods. The study included 972 consecutive patients admitted for NSTEACS (i.e. ST-segment depression or an elevated troponin-I level). Systolic dysfunction was defined as an ejection fraction <50% on transthoracic echocardiography. The primary long-term endpoint was death or myocardial infarction. The effect of invasive treatment on prognosis was evaluated …

Malemedicine.medical_specialtyAcute coronary syndromeEjection fractionbusiness.industrySystolemedicine.medical_treatmentHazard ratioGeneral MedicineRevascularizationmedicine.diseasePrognosisInternal medicineCardiologyClinical endpointMyocardial RevascularizationMedicineST segmentHumansFemaleMyocardial infarctionSystoleAcute Coronary SyndromebusinessAgedRevista espanola de cardiologia
researchProduct

Homocysteine and long-term recurrent infarction following an acute coronary syndrome.

2021

En Cardiology Journal. Gdańsk (Polonia) : Via Medica. Vol. 28, n. 4 (01 jul. 2021), pp. 598-606. ISSN 1897-5593. e-ISSN 1898-018X. Este artículo se encuentra disponible en la siguiente URL: https://journals.viamedica.pl/cardiology_journal/article/view/CJ.a2020.0170/52602 En este artículo de investigación también participan: Maria Marco, Teresa García-Ballester, Begoña Zorio, Eduardo Núñez, Francisco J. Chorro, Juan Sanchis y Julio Núñez. Background: There are no well-established predictors of recurrent ischemic coronary events after an acute coronary syndrome (ACS). Higher levels of homocysteine have been reported to be associated with an increased atherosclerotic burden. The primary endpoi…

Malemedicine.medical_specialtyAcute coronary syndromeHomocysteinemedicine.medical_treatmentCoronary heart disease - Risk factors.Infarto de miocardio - Factores de riesgo.Enfermedad coronaria - Factores de riesgo.InfarctionClinical CardiologyRevascularizationCoronary artery diseasechemistry.chemical_compoundInterquartile rangeRisk FactorsInternal medicineMyocardial infarction - Risk factors.medicineHumansMyocardial infarctionAcute Coronary SyndromeHomocysteineAgedacute coronary syndrome coronary artery disease homocysteine recurrent myocardial infarction risk factorsCardiovascular system - Diseases - Risk factors.Framingham Risk Scorebusiness.industryEnfermedades cardiovasculares - Factores de riesgo.General Medicinemedicine.diseaseHospitalizationchemistryCardiologyST Elevation Myocardial InfarctionCardiology and Cardiovascular MedicinebusinessCardiology journal
researchProduct

Differential Prognostic Effect of Revascularization According to a Simple Comorbidity Index in High-Risk Non-ST-Segment Elevation Acute Coronary Synd…

2011

Background: Data on the effect of revascularization on outcome in patients with high-risk non–ST-segment elevation acute coronary syndrome (NSTEACS) and significant comorbidities are scarce. Recently, a simple comorbidity index (SCI) including 5 comorbidities (renal failure, dementia, peripheral artery disease, heart failure, and prior myocardial infarction [MI]) has shown to be a useful tool for risk stratification. Nevertheless, therapeutic implications have not been derived. Hypothesis: We sought to evaluate the prognostic effect attributable to revascularization in NSTEACS according the SCI score. Methods: We included 1017 consecutive patients with NSTEACS. The effect of revascularizati…

Malemedicine.medical_specialtyAcute coronary syndromeTime Factorsmedicine.medical_treatmentDecision MakingStatistics as TopicClinical InvestigationsComorbidityKaplan-Meier EstimateRevascularizationRisk AssessmentInterquartile rangeInternal medicineConfidence IntervalsmedicineHealth Status IndicatorsHumansST segmentProspective StudiesMyocardial infarctionAcute Coronary SyndromePropensity ScoreAgedProportional Hazards Modelsbusiness.industryProportional hazards modelHazard ratioGeneral MedicineMiddle AgedPrognosismedicine.diseaseTroponinConfidence intervalSurgerySpainCardiologyFemaleCardiology and Cardiovascular MedicinebusinessClinical Cardiology
researchProduct

An Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes. From Large Trials to the Real World

2004

Introduction and objectives We report the impact on prognosis of an invasive strategy used at our center for non-ST-segment elevation acute coronary syndrome. Patients and method We analyzed 504 consecutive patients with typical chest pain, electrocardiographic changes or increased troponin I serum values, who were divided into 2 cohorts: a ) conservative group, 272 patients admitted between October 2001 and September 2002 and managed with a conservative strategy, and b ) invasive group, 232 patients admitted between October 2002 and September 2003 for whom an invasive strategy was recommended. We recorded major events (death or reinfarction) and minor events (readmission or need for post-d…

Malemedicine.medical_specialtyAcute coronary syndromemedicine.medical_treatmentMyocardial InfarctionChest painRevascularizationAngioplastyInternal medicinemedicineHumansST segmentAngina UnstableAgedUnstable anginabusiness.industryIncidence (epidemiology)AngioplastyHazard ratioSyndromeGeneral MedicinePrognosismedicine.diseaseSurgeryAcute DiseaseCardiologyFemalemedicine.symptombusinessRevista Española de Cardiología (English Edition)
researchProduct

Causes of ineligibility in randomized controlled trials and long-term mortality in patients with non-ST-segment elevation acute coronary syndromes

2006

To determine the long-term mortality of patients with non-ST-segment elevation acute coronary syndromes (NSTEACS) that are eligible versus those not eligible in randomized controlled trials (RCT), and how each exclusion criteria is associated with outcome.Common causes of exclusion in six published RCT on intravenous antithrombotic therapy were prospectively assessed in a cohort of 452 consecutive patients with NSTEACS that were followed for up to 3 years.Forty-one percent of patients had one or more exclusion criteria establishing the ineligible group. These patients were older, more likely to have coronary risk factors, ischemic ECG changes, heart failure at admission, higher creatinine l…

Malemedicine.medical_specialtyAcute coronary syndromemedicine.medical_treatmentRevascularizationlaw.inventionElectrocardiographyRandomized controlled trialRisk FactorslawInternal medicinemedicineHumansThrombolytic TherapyProspective StudiesAcute Coronary SyndromeProportional Hazards ModelsRandomized Controlled Trials as TopicEjection fractionbusiness.industryPatient SelectionMortality rateST elevationmedicine.diseaseSurgeryClinical trialTreatment OutcomeEchocardiographyCohortFemaleCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct